ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,258.61
0.00%
Dow Jones
44,860.31
0.28%
Gold vs US Dollar
2,646.685
0.55%
Brent Oil
72.655
0.28%
Bitcoin
93,364.87
1.51%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) News

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VKTX
DateTimeSourceHeadlineSymbolCompany
19/11/202421:03PR Newswire (US)Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024NASDAQ:VKTXViking Therapeutics Inc
12/11/202421:05PR Newswire (US)Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024NASDAQ:VKTXViking Therapeutics Inc
04/11/202411:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/11/202411:30PR Newswire (US)Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024NASDAQ:VKTXViking Therapeutics Inc
04/11/202411:20IH Market NewsTesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-MarketNASDAQ:VKTXViking Therapeutics Inc
31/10/202420:05PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
28/10/202420:05PR Newswire (US)Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024NASDAQ:VKTXViking Therapeutics Inc
25/10/202423:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
25/10/202420:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
24/10/202410:07IH Market NewsTesla Shares Rise 11% Pre-Market; IBM Falls 4% on Lower-Than-Expected Revenue; Apple Prepares New LaunchesNASDAQ:VKTXViking Therapeutics Inc
23/10/202421:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VKTXViking Therapeutics Inc
23/10/202420:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
23/10/202420:05PR Newswire (US)Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
23/10/202409:58IH Market NewsUS Futures Fall Amid Treasury Yield Surge and Earnings; Oil Prices Dip as U.S. Crude Inventories RiseNASDAQ:VKTXViking Therapeutics Inc
16/10/202420:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024NASDAQ:VKTXViking Therapeutics Inc
10/10/202410:45IH Market NewsTesla’s Robotaxi Day; GSK Settles 93% of Zantac Lawsuits; 10x Genomics Stock Drops on Revenue ForecastNASDAQ:VKTXViking Therapeutics Inc
09/10/202411:00PR Newswire (US)Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALDNASDAQ:VKTXViking Therapeutics Inc
21/09/202401:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
21/09/202401:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
21/09/202401:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
20/09/202420:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
28/08/202420:03PR Newswire (US)Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:VKTXViking Therapeutics Inc
22/08/202423:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
21/08/202420:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
20/08/202400:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
20/08/202400:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
31/07/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
31/07/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
30/07/202421:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
30/07/202421:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VKTX

Your Recent History

LSE
EZJ
Easyjet
LSE
SCLP
Scancell
LSE
VAST
Vast Resources
LSE
BARC
Barclays
LSE
GDR
Genedrive
LSE
EDEN
Eden Research
LSE
AAZ
Anglo Asian Mining
LSE
ZED
Zenova
LSE
GWMO
Great Western Mining
LSE
ENT
Entain
LSE
IPO
Ip
LSE
AML
Aston Martin Lagonda Glo...
LSE
UPS
LSE
BOO
Boohoo
LSE
ONT
Oxford Nanopore Technolo...
LSE
ALBA
Alba Mineral Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Gold Trader

    1 year 35%, 2 years 45% and *3 years 60%

    *Across 3 years £3655.44 only £1462.17